nach oben

Erschienen in:

19.03.2021 | Original Article

Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease

verfasst von: Jing-Lu Jin, Hui-Wen Zhang, Ye-Xuan Cao, Hui-Hui Liu, Qi Hua, Yan-Fang Li, Yan Zhang, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Ying Gao, Chuan-Jue Cui, Geng Liu, Jing Sun, Qian Dong, Jian-Jun Li

Erschienen in: Hepatology International | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Although non-invasive liver fibrosis scores (LFSs) have already been considered as effective tools for estimating cardiovascular risk, their roles in predicting disease severity and cardiovascular event (CVEs) in patients with stable coronary artery disease (CAD) are not comprehensively evaluated. The aim of the present study was to investigate whether non-alcoholic fatty liver disease fibrosis score (NAFLD-FS) and fibrosis-4 (FIB-4) are associated with CVEs in a large cohort with long-term follow-up.

Methods

A cohort of 5143 patients with angiography-proven stable CAD were consecutively enrolled and followed up for CVEs. The degree of coronary severity was assessed using the number of diseased vessels, Gensini, Syntax, and Jeopardy scores. The predictive values of NAFLD-FS and FIB-4 scores to coronary severity, coronary calcification (CAC), and CVEs were assessed, respectively.

Results

During a median follow-up of 7 years, 435 CVEs were recorded. Both NAFLD-FS and FIB-4 were predictors for the presence of CAC. The degree of coronary stenosis was significantly higher in high NAFLD-FS categories while FIB-4 was only positively associated with the number of diseased vessels and Gensini score. In Kaplan–Meier analysis, the patients with intermediate and high NAFLD-FS and FIB-4 had higher risk of CVEs and cardiovascular mortality. In multivariate Cox regression analysis, NAFLD-FS and FIB-4 were independently associated with CVEs [hazard ratio (95% confidence interval): 1.150 (1.063–1.244), p < 0.001 and 1.128 (1.026–1.240), p = 0.012].

Conclusion

The current data first indicated that both NAFLD-FS and FIB-4 scores were not only significantly related to coronary severity but also associated with CAC and CVEs.

Clinical trials registration

None.

Graphic abstract

Nur mit Berechtigung zugänglich

Olesen KKW, Madsen M, Gyldenkerne C, Thrane PG, Würtz M, Thim T, et al. Diabetes mellitus is associated with increased risk of ischemic stroke in patients with and without coronary artery disease. Stroke 2019;50(12):3347–3354CrossRef

Chen Q, Li Q, Li D, Chen X, Liu Z, Hu G, et al. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis 2020;299:45–52CrossRef

Presta V, Figliuzzi I, Miceli F, Coluccia R, Fogacci F, Cicero AFG, et al. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: analysis of a large real practice database in Italy. Atherosclerosis 2019;285:40–48CrossRef

Liu HH, Cao YX, Sun D, Jin JL, Guo YL, Wu NQ, et al. Impact of non-alcoholic fatty liver disease on cardiovascular outcomes in patients with stable coronary artery disease: a matched case-control study. Clin Transl Gastroenterol 2019;10(2):e00011CrossRef

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142(7):1592–1609CrossRef

Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol 2018;68(2):305–315CrossRef

Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57(4):1357–1365CrossRef

Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51(3):606CrossRef

Califf RM, Phillips HR 3rd, Hindman MC, Mark DB, Lee KL, Behar VS, et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 1985;5(5):1055–1063CrossRef

10.

McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112(5):740–751CrossRef

11.

Wong VW, Wong GL, Yeung JC, Fung CY, Chan JK, Chang ZH, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology 2016;63(3):754–763CrossRef

12.

Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol 2018;68(2):335–352CrossRef

13.

Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care 2018;41(2):341–347CrossRef

14.

Chang Y, Ryu S, Sung KC, Cho YK, Sung E, Kim HN, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut 2019;68(9):1667–1675CrossRef

15.

Garg H, Aggarwal S, Shalimar YR, Shalimar YR, Datta Gupta S, Agarwal L, et al. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Surg Obes Relat Dis 2018;14(1):81–91CrossRef

16.

Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51(3):433–445CrossRef

17.

Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013;145(4):782–789 (e4)CrossRef

18.

Chen Y, Xu M, Wang T, Sun J, Sun W, Xu B, et al. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis 2015;241(1):145–150CrossRef

19.

Xin Z, Zhu Y, Wang S, Liu S, Xu M, Wang T, et al. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score. Liver Int 2020;40(4):806–814CrossRef

20.

Turan Y. The nonalcoholic fatty liver disease fibrosis score is related to epicardial fat thickness and complexity of coronary artery disease. Angiology 2020;71(1):77–82CrossRef

21.

Lee SB, Park GM, Lee JY, Lee BU, Park JH, Kim BG, et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study. J Hepatol 2018;68(5):1018–1024CrossRef

22.

Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation 1995;92(8):2157–2162CrossRef

23.

Uebleis C, Becker A, Griesshammer I, Cumming P, Becker C, Schmidt M, et al. Stable coronary artery disease: prognostic value of myocardial perfusion SPECT in relation to coronary calcium scoring–long-term follow-up. Radiology 2009;252(3):682–690CrossRef

24.

Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 2017;66(2):323–329CrossRef

25.

Song DS, Chang UI, Kang SG, Song SW, Yang JM. Noninvasive serum fibrosis markers are associated with coronary artery calcification in patients with nonalcoholic fatty liver disease. Gut Liver 2019;13(6):658–668CrossRef

26.

Saito Y, Okumura Y, Nagashima K, Fukamachi D, Yokoyama K, Matsumoto N, et al. Impact of the Fibrosis-4 Index on Risk Stratification of Cardiovascular Events and Mortality in Patients with Atrial Fibrillation: Findings from a Japanese Multicenter Registry. J Clin Med 2020;9(2)

27.

De Vincentis A, Costanzo L, Vespasiani-Gentilucci U, Picardi A, Bandinelli S, Ferrucci L, et al. Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people. Dig Liver Dis 2019;51(9):1330–1336CrossRef

28.

Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol 2019;17(9):1877–1885 (e5)CrossRef

29.

Sato M, Kamada Y, Takeda Y, Kida S, Ohara Y, Fujii H, et al. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int 2015;35(3):925–935CrossRef

30.

Eleftheriadou I, Grigoropoulou P, Kokkinos A, Mourouzis I, Perrea D, Katsilambros N, et al. Association of plasma fetuin-a levels with peripheral arterial disease and lower extremity arterial calcification in subjects with type 2 diabetes mellitus. J Diabetes Complic 2017;31(3):599–604CrossRef

Titel: Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease
verfasst von: Jing-Lu Jin
Hui-Wen Zhang
Ye-Xuan Cao
Hui-Hui Liu
Qi Hua
Yan-Fang Li
Yan Zhang
Yuan-Lin Guo
Na-Qiong Wu
Cheng-Gang Zhu
Rui-Xia Xu
Ying Gao
Chuan-Jue Cui
Geng Liu
Jing Sun
Qian Dong
Jian-Jun Li
Publikationsdatum: 19.03.2021
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 2/2021
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-021-10167-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease